Which CDK4/6 drug is easiest to tolerate in early breast cancer?

NCT ID NCT07706933

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This trial compares how well patients tolerate dalpiciclib versus abemaciclib or ribociclib when each is combined with standard hormone therapy for high-risk HR+/HER2- early breast cancer. About 456 patients who have completed initial local treatment will be randomly assigned to one of the two groups. The main goal is to see which drug causes fewer dose reductions or early stops due to side effects within the first 12 weeks, while also tracking quality of life through patient questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dalpiciclib, abemaciclib, or ribociclib (CDK4/6 inhibitors) combined with standard endocrine therapy (letrozole, anastrozole, tamoxifen, or toremifene)
What this could lead to
If successful, this trial could identify a better-tolerated CDK4/6 inhibitor for high-risk early breast cancer, potentially improving quality of life and treatment adherence.
What could go wrong
This is a Phase NA trial with 456 participants, so results are preliminary and may not confirm superiority. Side effects like fatigue, nausea, or low blood counts are possible with these drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.